secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001157523-23-001018
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Aldeyra's ADX-2191 NDA for PVRL
-----------------------------------------------------------------------

- FDA cited lack of substantial evidence due to no adequate well-controlled studies in literature-based NDA.
- No safety or manufacturing issues identified in the Complete Response Letter.
- Aldeyra plans Expanded Access Program discussions with FDA due to methotrexate shortage and no approved PVRL therapy.
- ADX-2191 also under development for proliferative vitreoretinopathy and retinitis pigmentosa.
- Top-line Phase 2 results in retinitis pigmentosa expected to be announced June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001018/0001157523-23-001018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001018/a53427165.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer